Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Publikováno v:
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-7 (2020)
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-7 (2020)
Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation behaves d
Autor:
Yulin Chao, Ruiping He, Lu Zhang, Xiaojie Li, Junqiang Liu, Chuanchun Han, Wenzhi Zhao, Xishuang Song, Yi Yuan
Publikováno v:
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 16, Iss 1, Pp 1-11 (2018)
Cell Communication and Signaling, Vol 16, Iss 1, Pp 1-11 (2018)
Background Chemotherapeutic insensitivity remains a big challenge in prostate cancer treatment. Recently, increasing evidence has indicated that KLF4 plays a key role in prostate cancer. However, the potential biological role of KLF4 in Chemotherapeu